Imprida
amlodipine / valsartan
Table of contents
Overview
The marketing authorisation for Imprida has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Imprida
|
| Agency product number |
EMEA/H/C/000775
|
| Active substance |
|
| International non-proprietary name (INN) or common name |
|
| Therapeutic area (MeSH) |
Hypertension
|
| Anatomical therapeutic chemical (ATC) code |
C09DB01
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Novartis Europharm Ltd
|
| Revision |
20
|
| Date of issue of marketing authorisation valid throughout the European Union |
17/01/2007
|
| Contact address |
Frimley Business Park
Camberley GU16 7SR United Kingdom |
Product information
03/04/2017 Imprida - EMEA/H/C/000775 - WS/0709
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Agents acting on the renin-angiotensin system
Therapeutic indication
Treatment of essential hypertension.
Imprida is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.
Assessment history
News
-
28/06/2013
-
17/05/2013
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 201121/10/2011
-
20/10/2011
-
24/04/2008